Effects of Social Determinants of Health on IV Iron Treatments
Launched by BAYCARE HEALTH SYSTEM · Sep 7, 2024
Trial Information
Current as of July 04, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients receiving one of the following IV iron products: Ferric Carboxymaltose, Ferric Derisomaltose, Ferumoxytol, Iron Sucrose, or Iron Dextran
- • Patients 18 years of age or older
- • Patients who speak English or Spanish
- Exclusion Criteria:
- • Patients receiving an alternative IV iron product: Sodium ferric gluconate
- • Patients under 18 years of age
- • Patients who do not speak English or Spanish
About Baycare Health System
BayCare Health System is a leading not-for-profit healthcare organization based in the Tampa Bay area of Florida, dedicated to providing high-quality, compassionate care across a comprehensive network of hospitals, outpatient facilities, and home care services. As a clinical trial sponsor, BayCare is committed to advancing medical research and improving patient outcomes by facilitating innovative studies that explore new treatments and therapies. With a focus on collaboration and ethical practices, BayCare leverages its extensive healthcare expertise and resources to support clinical trials that address diverse health challenges, ensuring that patient safety and well-being remain paramount throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Patients applied
Trial Officials
Les Louden, PharmD, MS
Principal Investigator
BayCare Health System
Janelle Applequist, PhD
Principal Investigator
The University of South Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported